Ischaemic and non-ischaemic cardiomyopathies-cardiac MRI appearances with delayed enhancement

Clinical Radiology

Volumn 62, Issue 5, 2007, Pages 395-403

  Jackson, E ^a   Bellenger, N ^a   Seddon, M ^a   Harden, S ^a   Peebles, C ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOIDOSIS; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; FABRY DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART PERFUSION; HEART RIGHT VENTRICLE DYSPLASIA; HEART TUMOR; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTROPHIC CARDIOMYOPATHY; INTRACARDIAC THROMBOSIS; ISCHEMIC HEART DISEASE; MYOCARDITIS; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SARCOIDOSIS; TRYPANOSOMIASIS;

ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; HUMANS; HYPEREOSINOPHILIC SYNDROME; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33947582452     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2006.11.013     Document Type: Review

References (45)

1. Edelman R.R. Contrast-enhanced MR imaging of the heart: overview of the literature. Radiology 232 (2004) 653-668
2. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 (2000) 1445-1453
3. Sandstede J.J.W. Assessment of myocardial viability by MR imaging. Eur Radiol 13 (2003) 52-61
4. Mahrholdt H., Wagner A., Judd R.M., et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26 (2005) 1461-1474
5. Kim R.J., Shah D.J., and Judd R.M. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5 (2003) 505-514
6. Simonetti O.P., Kim R.J., Fieno D.S., et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218 (2001) 215-223
7. Crean A., and Merchant N. MR perfusion and delayed enhancement imaging in the heart. Clin Radiol 61 (2006) 225-236
8. Kuhl H.P., Papavasiliu T.S., Beek A.M., et al. Myocardial viability: rapid assessment with delayed contrast-enhanced MR imaging with three-dimensional inversion-recovery prepared pulse sequence. Radiology 230 (2004) 576-582
9. Foo T.K., Stanley D.W., Castillo E., et al. Myocardial viability: breath hold 3D MR imaging of delayed hyperenhancement with variable sampling in time. Radiology 230 (2004) 845-851
10. Tatli S., Zou K.H., Fruitman M., et al. Three dimensional magnetic resonance imaging technique for myocardial-delayed hyperenhancement: a comparison with the two dimensional technique. J Magn Reson Imaging 20 (2004) 378-382
11. Huber A.M., Schoenberg S.O., Hayes C., et al. Phase-sensitive inversion-recovery MR imaging in the detection of myocardial infarction. Radiology 237 (2005) 854-860
12. Hillenbrand H.B., Kim R.J., Parker M.A., et al. Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. Circulation 102 (2000) 1678-1683
13. Kim R.J., Chen E.L., Lima J.A., et al. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 94 (1996) 3318-3326
14. Bogaert J., Taylor A.M., Van Kerkhove F., et al. Use of inversion recovery contrast-enhanced MRI for cardiac imaging: spectrum of applications. AJR Am J Roentgenol 182 (2004) 609-615
15. Rehwald W.G., Fieno D.S., and Chen E.L. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischaemic injury. Circulation 105 (2002) 224-229
16. Van Hoe L., and Vanderheyden. Ischaemic cardiomyopathy: value of different MRI techniques for prediction of functional recovery after revascularization. AJR Am J Roentgenol 182 (2004) 95-100
17. Kaandorp T.A.M., Lamb H.J., Van der Wall E.E., et al. Cardiovascular MR to assess myocardial viability in chronic ischaemic LV dysfunction. Heart 91 (2005) 1359-1365
18. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 (1999) 1992-2002
19. Klein C., Nekolla S.G., and Bengel F.M. Assessment of Myocardial viability with contrast-enhanced magnetic resonance imaging. Comparison with positron emission tomography. Circulation 105 (2002) 162-167
20. Wagner A., Mahrholdt H., Holly T.A., et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 361 (2003) 374-379
21. Bellenger N., Peebles C., and Curzen N. Cardiovascular magnetic resonance for the interventionist. EuroIntervention 1 (2006) 445-453
22. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularisation on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39 (2002) 1151-1158
23. Dendale P., Franken P.R., Bolck P., et al. Contrast enhanced and functional magnetic resonance imaging for the detection of viable myocardium after infarction. Am Heart J 135 (1998) 875-880
24. Wu K.C., Zerhouni E.A., Judd R.M., et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97 (1998) 765-772
25. Bogaert J., Goldstein M., Tannouri F., et al. Late myocardial enhancement in hypertrophic cadiomyopathy with contrast-enhanced MR imaging. AJR Am J Roentgenol 180 (2003) 981-985
26. Choudhury L., Mahrholdt H., and Wagner A. Myocardial scarring in miminally symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 2156-2164
27. Moon J.C., McKenna W.J., and McCrohon J.A. Towards clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
28. Moon J.C., Reed E., and Sheppard M.N. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 (2004) 2260-2264
29. Flamm S.D., Villareal R.P., Hariharan R., et al. Delayed-enhancement MRI reveals myocardial fibrosis in patients with symptomatic hypertrophic cardiomyopathy. Proc Intl Soc Mag Reson 9 (2001) 226
30. Sievers B., Moon J.C., and Pennell D.J. Magnetic resonance contrast enhancement of iatrogenic septal myocardial infarction in hypertrophic cardiomyopathy. Circulation 105 (2002) 1018
31. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 (2003) 54-59
32. Koito H., Suzuki J., Ohkubo N., et al. Gadolinium-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging of dilated cardiomyopathy: clinical significance of abnormally high signal intensity of left ventricular myocarcium. J Cardiol 28 (1996) 41-49
33. Wassmuth R., Erdbruegger U., Lerizsch S., et al. Magnetic resonance imaging for monitoring cardiac function and tissue characterization in anthracyclines therapy. Circulation 102 Suppl. 2 (2000) 809-810
34. Maceira A.M., Joshi J., and Prasad S.K. CMR in amyloidosis. Circulation 111 (2005) 186-193
35. Patel M.R., Cawely P.J., and Heitner J.F. Improved diagnostic sensitivity of contrast enhanced cardiac MRI for cardiac sarcoidosis. Circulation 108 Suppl. (2004) 645
36. Doughan A.R., and Williams B.R. Cardiac sarcoidosis. Heart 92 (2006) 282-288
37. Mahrholdt H., Goedecke C., and Wagner A. Cardiovascular magnetic resonance assessment of human myocarditis; a comparison to histology and molecular pathology. Circulation 109 (2004) 1250-1258
38. Roditi G.H., Hartnell G.G., and Cohen M.C. MRI changes in myocarditis: evaluation with spin echo, cine MR angiography and contrast enhanced spin echo imaging. Clin Radiol 55 (2000) 752-758
39. Salanitri G.C. Endomyocardial fibrosis and intracardial thrombus occurring in idiopathic hypereosinophilic syndrome. AJR Am J Roentgenol 184 (2005) 1432-1433
40. Mollet N.R., Dymarkowski S., Volders W., et al. Visualisation of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischaemic heart disease. Circulation 106 (2002) 2873-2876
41. Barkhausen J., Hunold P., Schueler W., et al. Detection and characterisation of intracardiac thrombi: comparison of echocardiography and magnetic resonance imaging. Radiology 225 Suppl. P (2002) 626
42. McKenna W.J., Thiene G., Nava A., et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cadiology. Br Heart J 71 (1994) 215-218
43. Tandri H., Saranathan S., Rodriguez R., et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 98-103
44. Rochitte C.E., Olivera P.F., and Joalbo M. Chagas disease is characterised by specific pattern and location of myocardial delayed enhanced MRI. J Cardiovasc Magn Reson 5 (2003) 115
45. Moon J.C., Sachdev B., and Elkington A.G. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 (2003) 2151-2155